Qualtrics Survey | Qualtrics Experience Management

CCDI aims to create a pipeline for samples from pediatric/AYA cancer patients to be characterized at a molecular level. This 'molecular characterization' could include genomic, transcriptomic, proteomic, epigenomic, and metabolomic assays. This effort represents a major step in realizing the promise of precision oncology.

Please comment on research priorities or scientific questions that you feel should be of high priority in this area, and on how your research aligns with the CCDI goals.

What are the “must have” molecular characterizations and assays that will address your scientific or clinical questions? If you had access to any additional molecular characterizations beyond the "must haves", which other assays would be the most impactful to advance your work? Be specific with your descriptions and indicate which are must-have (e.g., germline whole genome sequencing under genomics and total RNA-sequencing under transcriptomics).